Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Dyadic International (NQ: DYAI )

1.340 +0.005 (+0.39%)
Streaming Delayed Price Updated: 4:00 PM EDT, Mar 23, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 14,651
Open 1.390
Bid (Size) 1.310 (5)
Ask (Size) 1.340 (4)
Prev. Close 1.335
Today's Range 1.305 - 1.390
52wk Range 1.120 - 3.560
Shares Outstanding 28,563,100
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year

Top News

More News
Dyadic to Report 2022 Year End Financial Results on Wednesday, March 29, 2023
From Dyadic International, Inc.
Via Globe NewsWire
Dyadic Provides Phase 1 Clinical Trial Update for its DYAI-100 COVID-19 Recombinant Protein RBD Booster Vaccine Candidate
From Dyadic International, Inc.
Via Globe NewsWire

Performance

YTD
-2.90%
-2.90%
1 Month
-7.59%
-7.59%
3 Month
+4.69%
+4.69%
6 Month
-27.17%
-27.17%
1 Year
-59.64%
-59.64%

More News

Read More
Dyadic to Present at Roth Investor Conference and Upcoming Industry Events
From Dyadic International, Inc.
Via Globe NewsWire
Recap: Dyadic International Q1 Earnings
Via Benzinga
India Funds Affordable COVID-19 Vaccine Candidate Using Dyadic's Platform
Via Benzinga
12 Health Care Stocks Moving In Friday's After-Market Session
Via Benzinga
Dyadic to Participate in Two Upcoming Investor Conferences
From Dyadic International, Inc.
Via Globe NewsWire
Dyadic Announces Initiation of Dosing of First-In-Human Phase 1 Trial to Demonstrate Clinical Safety and Antibody Response in Humans for DYAI-100 COVID-19 Recombinant Protein RBD Booster Vaccine Candidate
From Dyadic International, Inc.
Via Globe NewsWire
Why Phibro Shares Are Trading Higher Today?
Via Benzinga
Dyadic Announces Sale of Equity Interest in Alphazyme
From Dyadic International, Inc.
Via Globe NewsWire
Dyadic to Attend J.P. Morgan 41st Annual Healthcare Conference
From Dyadic International, Inc.
Via Globe NewsWire
Dyadic's DYAI-100 COVID-19 Vaccine Study Published in a Leading Peer-Reviewed Scientific Journal
From Dyadic International, Inc.
Via Globe NewsWire
Stocks That Hit 52-Week Lows On Monday
Via Benzinga
Dyadic to Present at Upcoming Industry and Investor Events in November
From Dyadic International, Inc.
Via Globe NewsWire
Dyadic to Report Third Quarter 2022 Financial Results on Thursday, November 10, 2022
From Dyadic International, Inc.
Via Globe NewsWire
Dyadic Receives Regulatory Approval to Initiate Phase 1 Clinical Trial to Demonstrate Clinical Safety and Efficacy in Humans for DYAI-100 COVID-19 Recombinant Protein RBD Booster Vaccine Candidate
From Dyadic International, Inc.
Via Globe NewsWire
Dyadic to Present Disruptive C1 Technology at World Vaccine Congress Europe Announcing Expansion of Influenza Pipeline with Enhanced Efficacy Potential
From Dyadic International, Inc.
Via Globe NewsWire
Dyadic International: Q2 Earnings Insights
Via Benzinga
Earnings Preview: Dyadic International
Via Benzinga
Dyadic to Report Second Quarter 2022 Financial Results on Wednesday, August 10, 2022
From Dyadic International, Inc.
Via Globe NewsWire
Dyadic International Earnings Perspective: Return On Capital Employed
Via Benzinga
The Daily Biotech Pulse: Sanofi-IGM Ink Antibody Drug Collaboration; NeoGenomics Sinks On CEO Departure, Q1 Warning; Decision Day For Akebia
Via Benzinga
Earnings Scheduled For March 29, 2022
Via Benzinga
A Preview Of Dyadic International's Earnings
Via Benzinga
The Week Ahead In Biotech (March 27-April 2): Lipocine, Akebia, Merck Await FDA Verdicts, Adcom Test For Amylyx, BioNTech Earnings And More
Via Benzinga
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.